Hepatic pharmacokinetics and pharmacodynamics with ombitasvir/paritaprevir/ritonavir plus dasabuvir treatment and variable ribavirin dosage
The Journal of Infectious Diseases Dec 19, 2017
Talal AH, et al. - This study was performed to examine whether ribavirin (RBV) coadministration modified the early rate of decline of hepatitis C virus (HCV) RNA in the liver vs plasma compartments. During the first 2 weeks of treatment, coadministration of RBV had a minimal visible impact on the plasma or liver kinetics of HCV RNA decline, regardless of RBV dosing.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
